Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT07625618
PHASE1

A Pharmacokinetic and Safety Study of MY008211A Tablets in Subjects With Impaired or Normal Hepatic Function

Sponsor: Wuhan Createrna Science and Technology Co., Ltd

View on ClinicalTrials.gov

Summary

This study is a single-center, non-randomized, open-label, parallel, single-dose study to evaluate the PK profile and safety of MY008211A Tablets in subjects with hepatic impairment.

Key Details

Gender

All

Age Range

18 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

24

Start Date

2024-09-20

Completion Date

2024-12-28

Last Updated

2026-06-04

Healthy Volunteers

No

Interventions

DRUG

MY008211A tablets

Each subject will take a single oral dose of 400 mg MY008211A Tablets under fasting conditions.

Locations (1)

The First Hospital of Jilin University

Jilin, Changchun, China